{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Hits New 52-Week High of $1.95
Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.95 on October 31, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 144.59% increase over the past year, despite being loss-making and not offering dividends.
Lineage Cell Therapeutics Hits New 52-Week High of $1.87
Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.87 on October 30, 2025, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has seen a 134.39% increase over the past year, despite being loss-making and lacking a dividend yield.
Lineage Cell Therapeutics Hits New 52-Week High of $1.85
Lineage Cell Therapeutics, Inc. has achieved a new 52-week high of USD 1.85, reflecting a significant year-over-year performance increase. With a market capitalization of USD 283 million, the company operates in a competitive biotechnology sector, reporting a negative return on equity and a unique financial structure.
Lineage Cell Therapeutics Hits New 52-Week High of $1.82
Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.82 on October 8, 2025, reflecting a significant one-year performance increase. With a market capitalization of USD 283 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, while operating in the biotechnology sector.
Lineage Cell Therapeutics Hits New 52-Week High of $1.72
Lineage Cell Therapeutics, Inc. has achieved a new 52-week high, highlighting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a significant increase in value over the past year, attracting attention for its innovative approaches despite being a loss-making entity.
Lineage Cell Therapeutics Hits New 52-Week High of $1.64
Lineage Cell Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant rise in its stock performance over the past year. With a market capitalization of USD 283 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite facing challenges such as ongoing losses and a negative return on equity.
Lineage Cell Therapeutics Hits New 52-Week High of $1.63
Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.63 on September 22, 2025, reflecting a 106.37% increase over the past year. With a market capitalization of USD 283 million, the company continues to face challenges, including a negative return on equity and a high price-to-book ratio.
Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?
As of September 10, 2025, Lineage Cell Therapeutics, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 208.46%.
Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?
Lineage Cell Therapeutics, Inc. is currently considered risky and overvalued due to its negative P/E ratio, poor returns on capital, and high EV to Sales ratio, despite impressive year-to-date stock returns that raise concerns about long-term sustainability.
Lineage Cell Therapeutics Hits New 52-Week High of $1.61
Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.61 on September 18, 2025, reflecting a significant one-year performance of 97.45%. The company, with a market cap of USD 283 million, faces challenges indicated by its negative return on equity and high price-to-book ratio.
Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?
Lineage Cell Therapeutics is currently considered overvalued and risky due to significant negative financial ratios, including a Price to Book Value of 1.95 and an EV to Sales ratio of 11.24, despite a recent stock performance that outpaced the S&P 500.
Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the trend has shifted to mildly bullish, supported by a bullish MACD and Bollinger Bands, despite some short-term weakness indicated by daily moving averages and mixed signals from KST.
Who are in the management team of Lineage Cell Therapeutics, Inc.?
As of March 2022, the management team of Lineage Cell Therapeutics, Inc. includes Chairman Alfred Kingsley, CEO Brian Culley, and several independent directors: Deborah Andrews, Don Bailey, Neal Bradsher, Stephen Farrell, and Michael Mulroy. This team combines executive leadership with independent governance.
What does Lineage Cell Therapeutics, Inc. do?
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for age-related degenerative diseases and serious medical conditions. As of March 2025, it has a market cap of $196.02 million, with net sales of $2 million and a net loss of $4 million.
How big is Lineage Cell Therapeutics, Inc.?
As of Jun 18, Lineage Cell Therapeutics, Inc. has a market capitalization of 196.02 million, with net sales of 9.56 million and a net profit of -16.16 million over the latest four quarters. The company reported shareholder's funds of 78.38 million and total assets of 113.22 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
